HECB1701301

HECB1701301 is an improved small molecule formulation of the NMDA receptor antagonist memantine, developed by Sunshine Lake Pharma (HEC Pharm) for the treatment of Alzheimer's disease. Classified as an "improved new drug" (Class 2.2) under China's NMPA guidelines, it is designed to optimize the delivery and therapeutic profile of memantine, specifically as an extended-release capsule formulation. The drug acts as an uncompetitive, moderate-affinity antagonist of the N-methyl-D-aspartate (NMDA) receptor, which helps to mitigate glutamate-induced excitotoxicity—a process implicated in the neuronal damage observed in moderate to severe Alzheimer's disease. By modulating glutamatergic signaling, HECB1701301 aims to improve cognitive function and slow clinical progression in affected patients while potentially offering improved patient compliance through a simplified dosing regimen compared to immediate-release versions.

Other names

Memantine Hydrochloride Extended-Release Capsules盐酸美金刚缓释胶囊